Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1261293 | 0.81 | PTGS2 (0.46) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL27966275 | 0.81 | CES2 (0.50) | GRM1MEN1CYP1A2KMT2ATDP1 | |
| SCHEMBL25660557 | 0.81 | GRM1 (0.53) | GRM1MEN1CYP1A2KMT2ATDP1 | |
| SCHEMBL20889385 | 0.81 | DPP7 (0.40) | SMN1; SMN2GAACES2CES1ESR1 | |
| SCHEMBL19682597 | 0.81 | DPP7 (0.40) | SMN1; SMN2GAACES2CES1ESR1 | |
| SCHEMBL29557378 | 0.81 | GAA (0.50) | GRM1MEN1CYP1A2KMT2ATDP1 | |
| SCHEMBL15430213 | 0.81 | GAA (0.50) | GRM1MEN1CYP1A2KMT2ATDP1 | |
| SCHEMBL27967493 | 0.81 | GAA (0.50) | GRM1MEN1CYP1A2KMT2ATDP1 | |
| SCHEMBL2628067 | 0.81 | GAA (0.50) | GRM1MEN1CYP1A2KMT2ATDP1 | |
| SCHEMBL7395018 | 0.80 | GRM1 (0.56) | GRM1MEN1CYP1A2KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132136-B2 | Pharmaceutical combination | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2600853-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| CN-103068379-A | Combinations comprising an atypical antipsychotic and a TAAR1 agonist | HOFFMANN LA ROCHE | 2013-04-24 | — | — | CN | disclosed |
| WO-2012016879-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | SEMINIS VEGETABLE SEEDS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | GRM1 56/4885MEN1 1916/4885CYP1A2 225/4885 |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | GRM1 56/4885MEN1 1916/4885CYP1A2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.